Oncotarget

Research Papers: Gerotarget (Focus on Aging):

Serotonin 6 receptor controls alzheimer’s disease and depression

Hyung-Mun Yun, Kyung-Ran Park, Eun-Cheol Kim, Sanghyeon Kim and Jin Tae Hong _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:26716-26728. https://doi.org/10.18632/oncotarget.5777

Metrics: PDF 1749 views  |   HTML 1497 views  |   ?  


Abstract

Hyung-Mun Yun1,*, Kyung-Ran Park2,*, Eun-Cheol Kim1, Sanghyeon Kim4 and Jin Tae Hong3

1 Department of Maxillofacial Tissue Regeneration, School of Dentistry and Research Center for Tooth and Periodontal Regeneration (MRC), Kyung Hee University, Seoul, Republic of Korea

2 Department of Oral & Maxillofacial Regeneration, Kyung Hee University, Seoul, Republic of Korea

3 College of Pharmacy and Medical Research Center, Chungbuk National University, Chungbuk, Republic of Korea

4 Stanley Brain Research Laboratory, Stanley Medical Research Institute, Rockville, MD, USA

* These authors have contributed equally to this work

Correspondence to:

Jin Tae Hong, email:

Sanghyeon Kim, email:

Keywords: 5-HT6R, serotonin, APBA1/2, alzheimer’s disease, depression

Received: August 19, 2015 Accepted: August 29, 2015 Published: September 22, 2015

Abstract

Alzheimer’s disease (AD) and depression in late life are one of the most severe health problems in the world disorders. Serotonin 6 receptor (5-HT6R) has caused much interest for potential roles in AD and depression. However, a causative role of perturbed 5-HT6R function between two diseases was poorly defined. In the present study, we found that a 5-HT6R antagonist, SB271036 rescued memory impairment by attenuating the generation of Aβ via the inhibition of γ-secretase activity and the inactivation of astrocytes and microglia in the AD mouse model. It was found that the reduction of serotonin level was significantly recovered by SB271036, which was mediated by an indirect regulation of serotonergic neurons via GABA. Selective serotonin reuptake inhibitor (SSRI), fluoxetine significantly improved cognitive impairment and behavioral changes. In human brain of depression patients, we then identified the potential genes, amyloid beta (A4) precursor protein-binding, family A, member 2 (APBA2), well known AD modulators by integrating datasets from neuropathology, microarray, and RNA seq. studies with correlation analysis tools. And also, it was demonstrated in mouse models and patients of AD. These data indicate functional network of 5-HT6R between AD and depression.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 5777